Transgenic Group (TSE:2342) Cyclically Adjusted Revenue per Share: 円626.84 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:2342 Transgenic Group Inc TSE:2342
62 GF Score
Price 円259.00
GF Value 円255.69
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Transgenic Group Cyclically Adjusted Revenue per Share?

Transgenic Group TSE:2342 +12.12% 62 Cyclically Adjusted Revenue per Share is 円626.84 as of Mar. 2026. GuruFocus rates TSE:2342 with a GF Score™ of 62/100 and a GF Value™ of 円255.69 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Transgenic Group's adjusted revenue per share for the three months ended in Mar. 2026 was 円208.923. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円626.84 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Transgenic Group's average Cyclically Adjusted Revenue Growth Rate was 11.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Transgenic Group was 36.30% per year. The lowest was 15.40% per year. And the median was 24.80% per year.

As of today (2026-08-13), Transgenic Group's current stock price is 円259.00. Transgenic Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円626.84. Transgenic Group's Cyclically Adjusted PS Ratio of today is 0.41.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Transgenic Group was 8.71. The lowest was 0.27. And the median was 1.49.


Transgenic Group  (TSE:2342) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Transgenic Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=259.00/626.84
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Transgenic Group was 8.71. The lowest was 0.27. And the median was 1.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Transgenic Group Cyclically Adjusted Revenue per Share Related Terms


Transgenic Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Transgenic Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgenic Group Cyclically Adjusted Revenue per Share Chart

Transgenic Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 344.17 417.89 494.27 0.00 626.84

Transgenic Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 571.52 589.13 612.00 626.84

TSE:2342 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Transgenic Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgenic Group Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgenic Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Transgenic Group's Cyclically Adjusted PS Ratio falls into.


TSE:2342
62GF Score
Transgenic Group Inc TSE:2342
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgenic Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Transgenic Group's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=208.923/112.7000*112.7000
=208.923

Current CPI (Mar. 2026) = 112.7000.

Transgenic Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 66.557 97.900 76.619
201606 27.545 98.100 31.644
201609 41.204 98.000 47.385
201612 38.658 98.400 44.276
201703 53.110 98.100 61.014
201706 23.605 98.500 27.008
201709 35.249 98.800 40.208
201712 37.728 99.400 42.776
201803 134.039 99.200 152.280
201806 125.433 99.200 142.503
201809 132.399 99.900 149.363
201812 123.494 99.700 139.597
201903 129.512 99.700 146.399
201906 135.399 99.800 152.900
201909 163.529 100.100 184.113
201912 155.495 100.500 174.371
202003 181.614 100.300 204.067
202006 127.081 99.900 143.364
202009 142.416 99.900 160.663
202012 182.949 99.300 207.637
202103 183.560 99.900 207.079
202106 190.225 99.500 215.461
202109 194.780 100.100 219.298
202112 172.993 100.100 194.768
202203 174.151 101.100 194.133
202206 146.903 101.800 162.632
202209 182.385 103.100 199.368
202212 173.318 104.100 187.636
202303 175.913 104.400 189.898
202306 194.598 105.200 208.471
202309 183.447 106.200 194.675
202312 199.650 106.800 210.679
202403 201.099 107.200 211.417
202406 173.720 108.200 180.945
202409 206.415 108.900 213.618
202503 0.000 111.100 0.000
202506 192.034 111.700 193.753
202509 181.764 112.000 182.900
202512 208.393 113.000 207.840
202603 208.923 112.700 208.923

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円626.84 mean?
Transgenic Group (TSE:2342) has a Cyclically Adjusted Revenue per Share of 円626.84 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Transgenic Group and its competitors.
Is Transgenic Group's Cyclically Adjusted Revenue per Share too high?
Transgenic Group's current Cyclically Adjusted Revenue per Share is 円626.84. Overall, Transgenic Group has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Transgenic Group's Cyclically Adjusted Revenue per Share of 円626.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Transgenic Group and its competitors. Transgenic Group's current Cyclically Adjusted Revenue per Share is 円626.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Fairly Valued. The stock's GF Value™ is 円255.69, compared to a current price of 円259.00 — trading 1.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円626.84. Transgenic Group's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Cyclically Adjusted Revenue per Share is 円626.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgenic Group (TSE:2342) Overvalued in 2026?

Based on GuruFocus' analysis, Transgenic Group stock appears to be overvalued. The current stock price of 円259.00 is trading 1.3% above its estimated GF Value™ of 円255.69. GuruFocus considers Transgenic Group to be Fairly Valued.

Key valuation signals for TSE:2342:

  • Cyclically Adjusted Revenue per Share: 円626.84
  • GF Value™: 円255.69 vs. price of 円259.00 (1.3% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Transgenic Group Business Description

Address 2-3-36 Tenjin, Chuo-ku, Fukuoka Prefecture, Fukuoka, JPN
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
62GF Score

Get the complete analysis for TSE:2342

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円259.00
Price
円255.69
GF Value